Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for +publisher:"The Ohio State University" +contributor:("Byrd, John"). Showing records 1 – 12 of 12 total matches.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


The Ohio State University

1. Herman, Sarah Elizabeth May. MANIPULATION OF KINASE SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE EFFECT ON DISEASE STATE.

Degree: PhD, Integrated Biomedical Science Graduate Program, 2010, The Ohio State University

  Chronic lymphocytic leukemia (CLL) has long been incorrectly labeled “the good leukemia” due to the age of onset and the low incidence of detectable… (more)

Subjects/Keywords: Biology; CLL; Phosphatidylinositol 3-kinase; Bruton's tyrosine kinase; lenalidomide; CAL-101; PCI-32765

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Herman, S. E. M. (2010). MANIPULATION OF KINASE SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE EFFECT ON DISEASE STATE. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1291046222

Chicago Manual of Style (16th Edition):

Herman, Sarah Elizabeth May. “MANIPULATION OF KINASE SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE EFFECT ON DISEASE STATE.” 2010. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1291046222.

MLA Handbook (7th Edition):

Herman, Sarah Elizabeth May. “MANIPULATION OF KINASE SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE EFFECT ON DISEASE STATE.” 2010. Web. 17 Jun 2019.

Vancouver:

Herman SEM. MANIPULATION OF KINASE SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE EFFECT ON DISEASE STATE. [Internet] [Doctoral dissertation]. The Ohio State University; 2010. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1291046222.

Council of Science Editors:

Herman SEM. MANIPULATION OF KINASE SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: THE EFFECT ON DISEASE STATE. [Doctoral Dissertation]. The Ohio State University; 2010. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1291046222


The Ohio State University

2. Triantafilllou, Georgia. CD74 Targeted Nanoparticles as Dexamethasone Delivery System for B lymphoid Malignancies.

Degree: PhD, Integrated Biomedical Science Graduate Program, 2011, The Ohio State University

 Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia and is not curable with standard therapy. In CLL the B lymphocytes appear morphologically mature… (more)

Subjects/Keywords: CLL; dexamethasone; liposomes; milatuzumab

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Triantafilllou, G. (2011). CD74 Targeted Nanoparticles as Dexamethasone Delivery System for B lymphoid Malignancies. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1307069335

Chicago Manual of Style (16th Edition):

Triantafilllou, Georgia. “CD74 Targeted Nanoparticles as Dexamethasone Delivery System for B lymphoid Malignancies.” 2011. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1307069335.

MLA Handbook (7th Edition):

Triantafilllou, Georgia. “CD74 Targeted Nanoparticles as Dexamethasone Delivery System for B lymphoid Malignancies.” 2011. Web. 17 Jun 2019.

Vancouver:

Triantafilllou G. CD74 Targeted Nanoparticles as Dexamethasone Delivery System for B lymphoid Malignancies. [Internet] [Doctoral dissertation]. The Ohio State University; 2011. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1307069335.

Council of Science Editors:

Triantafilllou G. CD74 Targeted Nanoparticles as Dexamethasone Delivery System for B lymphoid Malignancies. [Doctoral Dissertation]. The Ohio State University; 2011. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1307069335


The Ohio State University

3. Rafiq, Sarwish. Evaluation of Antibody-based Therapeutics in B cell Malignancies.

Degree: PhD, Integrated Biomedical Science Graduate Program, 2012, The Ohio State University

 Monoclonal antibodies therapy for B cell malignancies evolved vastly over the past few decades. Since its approval as the first therapeutic antibody for cancer, rituximab… (more)

Subjects/Keywords: Oncology; Therapy; CD37; CD20; Protein Therapeutics; Antibody Therapeutics

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Rafiq, S. (2012). Evaluation of Antibody-based Therapeutics in B cell Malignancies. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1338321515

Chicago Manual of Style (16th Edition):

Rafiq, Sarwish. “Evaluation of Antibody-based Therapeutics in B cell Malignancies.” 2012. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1338321515.

MLA Handbook (7th Edition):

Rafiq, Sarwish. “Evaluation of Antibody-based Therapeutics in B cell Malignancies.” 2012. Web. 17 Jun 2019.

Vancouver:

Rafiq S. Evaluation of Antibody-based Therapeutics in B cell Malignancies. [Internet] [Doctoral dissertation]. The Ohio State University; 2012. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1338321515.

Council of Science Editors:

Rafiq S. Evaluation of Antibody-based Therapeutics in B cell Malignancies. [Doctoral Dissertation]. The Ohio State University; 2012. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1338321515


The Ohio State University

4. Chen, Shih-Shih. Transcriptional Silencing Of Foxd3 Is An Early Event Mediating Epigenetic Silencing In Tcl1 Positive Chronic Lymphocytic Leukemia.

Degree: PhD, Molecular Genetics, 2008, The Ohio State University

 Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults; recent findings in CLL diagnosis, mechanism of pathogenesis and therapy… (more)

Subjects/Keywords: Biomedical Research; TCL1; CLL; FOXD3; DNA methylation

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Chen, S. (2008). Transcriptional Silencing Of Foxd3 Is An Early Event Mediating Epigenetic Silencing In Tcl1 Positive Chronic Lymphocytic Leukemia. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1214923446

Chicago Manual of Style (16th Edition):

Chen, Shih-Shih. “Transcriptional Silencing Of Foxd3 Is An Early Event Mediating Epigenetic Silencing In Tcl1 Positive Chronic Lymphocytic Leukemia.” 2008. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1214923446.

MLA Handbook (7th Edition):

Chen, Shih-Shih. “Transcriptional Silencing Of Foxd3 Is An Early Event Mediating Epigenetic Silencing In Tcl1 Positive Chronic Lymphocytic Leukemia.” 2008. Web. 17 Jun 2019.

Vancouver:

Chen S. Transcriptional Silencing Of Foxd3 Is An Early Event Mediating Epigenetic Silencing In Tcl1 Positive Chronic Lymphocytic Leukemia. [Internet] [Doctoral dissertation]. The Ohio State University; 2008. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1214923446.

Council of Science Editors:

Chen S. Transcriptional Silencing Of Foxd3 Is An Early Event Mediating Epigenetic Silencing In Tcl1 Positive Chronic Lymphocytic Leukemia. [Doctoral Dissertation]. The Ohio State University; 2008. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1214923446


The Ohio State University

5. Liu, Ta-Ming. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315.

Degree: PhD, Molecular, Cellular and Developmental Biology, 2014, The Ohio State University

 Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in western countries. Despite the improvement of treatment that is contributed by development of targeted… (more)

Subjects/Keywords: Biomedical Research; Ibrutinib resistance, OSU-T315

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Liu, T. (2014). Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1404917090

Chicago Manual of Style (16th Edition):

Liu, Ta-Ming. “Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315.” 2014. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1404917090.

MLA Handbook (7th Edition):

Liu, Ta-Ming. “Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315.” 2014. Web. 17 Jun 2019.

Vancouver:

Liu T. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [Internet] [Doctoral dissertation]. The Ohio State University; 2014. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1404917090.

Council of Science Editors:

Liu T. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [Doctoral Dissertation]. The Ohio State University; 2014. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1404917090


The Ohio State University

6. Liu, Qing. Targeting Protein Phosphatase 2a as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.

Degree: PhD, Pharmacy, 2008, The Ohio State University

 Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the western world. Despite significant progress in recent years, most patients eventually… (more)

Subjects/Keywords: Pharmaceuticals; FTY720; Lenalidomide; chronic lymphocytic leukemia; mantle cell lymphoma; PP2A

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Liu, Q. (2008). Targeting Protein Phosphatase 2a as a Therapeutic Strategy for Chronic Lymphocytic Leukemia. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1213301219

Chicago Manual of Style (16th Edition):

Liu, Qing. “Targeting Protein Phosphatase 2a as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.” 2008. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1213301219.

MLA Handbook (7th Edition):

Liu, Qing. “Targeting Protein Phosphatase 2a as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.” 2008. Web. 17 Jun 2019.

Vancouver:

Liu Q. Targeting Protein Phosphatase 2a as a Therapeutic Strategy for Chronic Lymphocytic Leukemia. [Internet] [Doctoral dissertation]. The Ohio State University; 2008. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1213301219.

Council of Science Editors:

Liu Q. Targeting Protein Phosphatase 2a as a Therapeutic Strategy for Chronic Lymphocytic Leukemia. [Doctoral Dissertation]. The Ohio State University; 2008. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1213301219


The Ohio State University

7. McWilliams, Emily Mary. Restoring Innate NK-cell Immunity with Antibody Therapeutics in CLL B-Cell Malignancy.

Degree: PhD, Biomedical Sciences, 2016, The Ohio State University

 Chronic Lymphocytic Leukemia (CLL) is the most prevalent adult leukemia with estimations in the US of over 18, 900 newly diagnosed cases and 4,600 deaths… (more)

Subjects/Keywords: Biomedical Research; CLL; antibody therapeutics; NK cells; immunotherapy; immunosuppression

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

McWilliams, E. M. (2016). Restoring Innate NK-cell Immunity with Antibody Therapeutics in CLL B-Cell Malignancy. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1479863842166353

Chicago Manual of Style (16th Edition):

McWilliams, Emily Mary. “Restoring Innate NK-cell Immunity with Antibody Therapeutics in CLL B-Cell Malignancy.” 2016. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1479863842166353.

MLA Handbook (7th Edition):

McWilliams, Emily Mary. “Restoring Innate NK-cell Immunity with Antibody Therapeutics in CLL B-Cell Malignancy.” 2016. Web. 17 Jun 2019.

Vancouver:

McWilliams EM. Restoring Innate NK-cell Immunity with Antibody Therapeutics in CLL B-Cell Malignancy. [Internet] [Doctoral dissertation]. The Ohio State University; 2016. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1479863842166353.

Council of Science Editors:

McWilliams EM. Restoring Innate NK-cell Immunity with Antibody Therapeutics in CLL B-Cell Malignancy. [Doctoral Dissertation]. The Ohio State University; 2016. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1479863842166353


The Ohio State University

8. Hing, Zachary Andrew. Targeting Nuclear Export in Chronic Lymphocytic Leukemia.

Degree: PhD, Biomedical Sciences, 2018, The Ohio State University

 In the past decade there has been increased appreciation for the complexity and importance of post-transcriptional processes that control gene regulation and post-translational processes that… (more)

Subjects/Keywords: Biomedical Research; Leukemia; B-cell; targeted therapies; nuclear export

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Hing, Z. A. (2018). Targeting Nuclear Export in Chronic Lymphocytic Leukemia. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1523543484958313

Chicago Manual of Style (16th Edition):

Hing, Zachary Andrew. “Targeting Nuclear Export in Chronic Lymphocytic Leukemia.” 2018. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1523543484958313.

MLA Handbook (7th Edition):

Hing, Zachary Andrew. “Targeting Nuclear Export in Chronic Lymphocytic Leukemia.” 2018. Web. 17 Jun 2019.

Vancouver:

Hing ZA. Targeting Nuclear Export in Chronic Lymphocytic Leukemia. [Internet] [Doctoral dissertation]. The Ohio State University; 2018. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1523543484958313.

Council of Science Editors:

Hing ZA. Targeting Nuclear Export in Chronic Lymphocytic Leukemia. [Doctoral Dissertation]. The Ohio State University; 2018. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1523543484958313


The Ohio State University

9. Rozewski, Darlene M. Pharmacokinetics and P-glycoprotein-Mediated Transport of the Leading IMiDs in Mice.

Degree: PhD, Pharmacy, 2012, The Ohio State University

 Lenalidomide and pomalidomide belong to a novel class of immunomodulatory (IMiD) drugs and have anti-angiogenic, anti-inflammatory, pro-erythropoietic and further anti-cancer activities. Both agents have shown… (more)

Subjects/Keywords: Pharmaceuticals; Lenalidomide; Pharmacokinetics; Mouse; P-glycoprotein; Disposition; Bioavailability; Transporter

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Rozewski, D. M. (2012). Pharmacokinetics and P-glycoprotein-Mediated Transport of the Leading IMiDs in Mice. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1331144282

Chicago Manual of Style (16th Edition):

Rozewski, Darlene M. “Pharmacokinetics and P-glycoprotein-Mediated Transport of the Leading IMiDs in Mice.” 2012. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1331144282.

MLA Handbook (7th Edition):

Rozewski, Darlene M. “Pharmacokinetics and P-glycoprotein-Mediated Transport of the Leading IMiDs in Mice.” 2012. Web. 17 Jun 2019.

Vancouver:

Rozewski DM. Pharmacokinetics and P-glycoprotein-Mediated Transport of the Leading IMiDs in Mice. [Internet] [Doctoral dissertation]. The Ohio State University; 2012. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1331144282.

Council of Science Editors:

Rozewski DM. Pharmacokinetics and P-glycoprotein-Mediated Transport of the Leading IMiDs in Mice. [Doctoral Dissertation]. The Ohio State University; 2012. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1331144282

10. Harrington, Bonnie K. Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma.

Degree: PhD, Comparative and Veterinary Medicine, 2018, The Ohio State University

 Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton’s Tyrosine Kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In these studies, we evaluated… (more)

Subjects/Keywords: Biomedical Research

…approved by The Ohio State University Veterinary Medical Center Clinical Research Advisory… 

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Harrington, B. K. (2018). Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1531911818180297

Chicago Manual of Style (16th Edition):

Harrington, Bonnie K. “Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma.” 2018. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1531911818180297.

MLA Handbook (7th Edition):

Harrington, Bonnie K. “Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma.” 2018. Web. 17 Jun 2019.

Vancouver:

Harrington BK. Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma. [Internet] [Doctoral dissertation]. The Ohio State University; 2018. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1531911818180297.

Council of Science Editors:

Harrington BK. Activity of the Second Generation BTK Inhibitor Acalabrutinib in Canine and Human B-cell Non-Hodgkin Lymphoma. [Doctoral Dissertation]. The Ohio State University; 2018. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1531911818180297

11. Browning, Rebekah L. Combination Therapies with Interleukin-21 in Chronic Lymphocytic Leukemia.

Degree: PhD, Integrated Biomedical Science Graduate Program, 2015, The Ohio State University

 Chronic lymphocytic leukemia (CLL) is the most common adult leukemia, with over 15,000 new cases diagnosed in the United States each year. CLL is characterized… (more)

Subjects/Keywords: Biomedical Research; Immunology; CLL; IL-21; lenalidomide; CpG ODN

…baccalaureate premedical curriculum, The Ohio State University 2005-2006… …Research assistant, The Ohio State University 2006-2008… …Medical student, The Ohio State University College of Medicine 2008-2010… …Howard Hughes Medical Institute Research Training Fellow, The Ohio State University 2010 to… …Fellow, The Ohio State University vii Publications Browning, RL; Mo, X; Muthusamy, N; Byrd… 

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Browning, R. L. (2015). Combination Therapies with Interleukin-21 in Chronic Lymphocytic Leukemia. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1429719855

Chicago Manual of Style (16th Edition):

Browning, Rebekah L. “Combination Therapies with Interleukin-21 in Chronic Lymphocytic Leukemia.” 2015. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1429719855.

MLA Handbook (7th Edition):

Browning, Rebekah L. “Combination Therapies with Interleukin-21 in Chronic Lymphocytic Leukemia.” 2015. Web. 17 Jun 2019.

Vancouver:

Browning RL. Combination Therapies with Interleukin-21 in Chronic Lymphocytic Leukemia. [Internet] [Doctoral dissertation]. The Ohio State University; 2015. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1429719855.

Council of Science Editors:

Browning RL. Combination Therapies with Interleukin-21 in Chronic Lymphocytic Leukemia. [Doctoral Dissertation]. The Ohio State University; 2015. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1429719855

12. Gupta, Sneha Veeraraghavan. Targeting Protein Metabolism in B-cell Malignancies.

Degree: PhD, Pharmacy, 2012, The Ohio State University

 Protein metabolism comprises the biochemical processes that regulate the synthesis of proteins, their post-translational modification and degradation. In cancer cells, pathways targeting protein metabolism are… (more)

Subjects/Keywords: CLL; Protein Metabolism; Carfilzomib; Silvestrol; acute lymphoblastic leukemia; chronic lymphocytic leukemia

…Graduate Teaching Associate, Division of Pharmaceutics, The Ohio State University 2008 to present… …Graduate Research Associate, Division of Pharmaceutics, The Ohio State University PUBLICATIONS… 

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Gupta, S. V. (2012). Targeting Protein Metabolism in B-cell Malignancies. (Doctoral Dissertation). The Ohio State University. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=osu1343169973

Chicago Manual of Style (16th Edition):

Gupta, Sneha Veeraraghavan. “Targeting Protein Metabolism in B-cell Malignancies.” 2012. Doctoral Dissertation, The Ohio State University. Accessed June 17, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1343169973.

MLA Handbook (7th Edition):

Gupta, Sneha Veeraraghavan. “Targeting Protein Metabolism in B-cell Malignancies.” 2012. Web. 17 Jun 2019.

Vancouver:

Gupta SV. Targeting Protein Metabolism in B-cell Malignancies. [Internet] [Doctoral dissertation]. The Ohio State University; 2012. [cited 2019 Jun 17]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1343169973.

Council of Science Editors:

Gupta SV. Targeting Protein Metabolism in B-cell Malignancies. [Doctoral Dissertation]. The Ohio State University; 2012. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=osu1343169973

.